Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Explored by GlobalData in Its Topical Study Available at

28 Mar 2016 • by Natalie Aster

LONDON – The value of the world market for methicillin-resistant staphylococcus aureus (MRSA) (including patients hospitalized with MRSA skin infections, bactermia or pneumonia in the 7 major markets) was estimated at approximately USD 1.4 billion in the year 2014. By 2024, this market is expected to exceed USD 1.45 billion, registering a 0.4% CAGR during 2016-2024. The US is likely to contribute the largest market share of around 71% in the years to come. It is distantly followed by Japan, accounting for a 16% market share. Further MRSA market growth is expected to be spurred by launches of new antimicrobial agents with potent activity against MRSA.

At the present day, the world MRSA market is characterized as highly competitive: physicians have a range of antimicrobial agents (approved to treat these severe and even life-threatening infections) at their disposal. Currently, there are more than 10 marketed antibiotics, which demonstrated potent activity against MRSA and are often used in treatment of invasive infections in the hospital setting.

The topical report “PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024” prepared by GlobalData presents a detailed study of the worldwide MRSA marketplace. It includes an overview of MRSA infections with details on etiology, epidemiology, symptoms, pathophysiology, diagnosis and also existing management strategies. The report offers access to the updated statistics on the MRSA market revenues, major pipeline product sales and annual cost of therapy (ACOT); presents a detailed coverage of the existing treatment options, pinpoints unmet needs, outlines the emerging opportunities, examines key drivers and barriers of the further MRSA market growth. The report provides a comprehensive pipeline analysis, delves deep into the competitive environment, reviews the performance of the dominant market players and also gives forecasts of the global MRSA market possible development through 2024.

Report Details:

PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024
Pages: 427
Published: December, 2015
Price: US$ 10,995.00

Many other in-demand research reports created by GlobalData can be found in this Market Publishers’ catalogue.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970